background: To understand which genes are really involved in the implantation process, we planned to study the gene basal expression profile during the window of implantation (WOI) of patients who became pregnant in a subsequent ICSI cycle.
Introduction
Biomolecular mechanisms that are involved in the embryo implantation process are still unknown. This event, like all complex biological mechanisms, depends on the activity of several factors of both embryonic and endometrial origin.
Researchers have tried to identify these factors and to understand the specific role of each of them. Until now, there has been no comprehensive theory which can explain this complex event.
It is clear that no single 'key' factor responsible for the attachment of the embryo exists. It is likely that several factors are needed, interacting with each other and forming a cascade of molecular signaling.
Our interest has been focused on the analysis of endometrial receptivity which represents a crucial moment of the menstrual cycle with a great relevance for pregnancy; understanding it remains one of the main goals for researchers working in the field of human reproduction.
In natural cycles, the ovary releases one oocyte in each standard menstrual cycle, 14 days before the subsequent menstruation. After fertilization, the embryo arrives in the endometrium at the blastocyst stage (day 5-6). At that moment, the endometrium is receptive to blastocyst implantation, in a synchronized manner with the development of the embryo. It is well established that implantation of the embryo in the uterine wall is possible only during a (steroid dependent) short period of time, called 'window of implantation' (WOI) in the mid-secretory phase (Harper, 1992; Wilcox et al., 1999) .
In this specific period, the endometrium is demonstrably different when compared with the non-receptive period; various growth factors, cytokines, transcription factors, apoptotic factors and other molecules, regulated by steroid hormones, are involved in this dramatic tissue modification (Hoozemans et al., 2004; Guzeloglu-Kayisli et al., 2007) .
During the WOI, several histological and molecular changes occur in the endometrium. For decades, endometrial dating in the WOI was been done only by histological features (Noyes et al., 1950 (Noyes et al., , 1975 . However, this was found not to be accurately predictive of a fertile endometrium (Murray et al., 2004) . Scanning electron microscopy (SEM) has also been used to date and assess endometrial maturation; in particular, this technology was used specifically for the detection of the pinopodes on the apical surface of the endometrial cells, which for a long time have been considered an index of the WOI (Noyes et al., 1975; Nikas, 1999; Sharkey and Smith, 2003) . Nevertheless, certain authors have recently reported that using pinopodes as a method of scoring endometrial 'receptivity' is also not entirely effective, because pinopodes are present throughout the luteal phase and up to the 11th week of pregnancy (Quinn et al., 2007) . It should be added that SEM technology is not usefully employable in daily clinical practice.
Another important step in the study of the endometrium was represented by the detection of the nuclear estrogen and progesterone receptor by immunohistochemical analysis, this first emerging at the end of the 1980s (Lessey et al., 1988) . The importance of the detection of estrogen and progesterone receptors by immunohistochemical analysis has been demonstrated in a recent article (Van der Gaast et al., 2008) , where ovarian stimulation did not alter the expression of these markers of endometrial maturation in the mid-luteal phase.
With the advent of the genomic era, new perspectives have opened up regarding the analysis of endometrial receptivity.
Gene expression analysis allows us to evaluate the gene transcriptional activity which is a potential indicator of protein production.
This technology has been proposed to evaluate gene expression in the endometrium during the WOI compared with the non-receptive period (proliferative phase and early secretory phase). Using microarray technology, and verified by RT -PCR it has been shown that gene expression profiles change in the endometrium (Carson et al., 2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al., 2003; Ponnampalam et al., 2004; Mirkin et al., 2005; Haouzi et al., 2009) . This technology provides semi-quantitative measurements of large numbers of mRNA transcripts in a single sample; any single gene is classified as being up-or down-regulated when its expression (during the receptive versus non-receptive period) increases or decreases, and these differences are evaluated as fold changes.
On analyzing these studies, several genes were shown to be up-or down-regulated during the receptive period; however, data from these five different studies are contradictory. Despite the authors having identified changes in expression of approximately 500 -600 genes, only two genes (osteopontin and IL-15) were significantly up-regulated in all studies. The precise role of gene expression changes during the WOI has not been properly understood, and any questions arising regarding the physiology of the endometrial receptivity are still being debated.
Although it has been postulated that the genes changing their expression profile during the WOI are determinant in the process of embryo implantation, we cannot confirm that all of these genes are really involved in the embryo implantation process.
There is very little available data correlating the gene expression profile and the clinical outcomes of IVF cycles. A recent article (Bersinger et al., 2008) investigated gene transcription rates and expression profiles in implantation failure, recurrent miscarriages and ongoing pregnancies, after IVF treatment. Seven genes showed up-or down-regulation between the miscarriage and ongoing pregnancies group, but the clinical significance of these genes has not been elucidated.
The primary objective of this study was to correlate the endometrial gene expression profile to the clinical outcomes of the ICSI cycles, in order to further clarify the role of some of these genes during the implantation process. To achieve this goal, we used a different approach, which, as far as we know, has not previously been attempted. Assuming that a 'good endometrium' is essential for achieving the pregnancy, we analyzed the gene expression profiles in endometrial tissues from women who subsequently became pregnant.
We chose this approach (i.e. the analysis of the gene expression profile in patients all having the same characteristic of being pregnant) instead of the more obvious comparison of the profiles of two cohorts of patients with different characteristics (pregnant or non-pregnant), because the ideal gene expression profile is, thus far, unknown. Furthermore, pregnancy is an event which is strongly influenced by multiple variables (many of these related to the embryo quality and to the embryo transfer procedure) so that the comparison between pregnant and non-pregnant patients might be biased. A patient could fail to become pregnant, after an IVF cycle, despite having a receptive endometrium and an ideal gene expression profile, because of poor quality embryos or a difficult embryo transfer procedure. Thus, due to the fact that they all subsequently became pregnant, the group of patients we selected possesses an endometrium which is 'functionally good'.
To achieve the objective of the study, we selected those genes which, on the basis of the published studies (Carson et al., 2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al., 2003; Mirkin et al., 2005) showed the strongest up-(23) or down-(11) regulation during the WOI period. It is assumed that these genes have a role in the implantation process but, until now, this role has not been clinically demonstrated.
We also included 13 genes involved in the apoptosis pathway. This choice hinged on the fact that implantation is followed by a local immune response characterized by the presence of a large population of T cells and by the activation of the Fas/Fas ligand system. Fas ligand is a protein which belongs to the TNF family; it is present in the trophoblast and it induces apoptosis of T cells through the link to the membrane receptor Fas. The activation of the Fas/Fas ligand system determines a cascade of events which lead to apoptosis. In details, this programmed cellular death occurs via an adapter protein called Fas-associated death domain (FADD). This factor contains a death domain that binds to a domain of caspase-8. Caspase-8 activates other factors, such as caspase-9. This cascade of activated factors leads the T cell to apoptosis. All these genes have been included in our analysis. The described events seem to play an important role in the acceptance of pregnancy (Aagard-Tillery et al., 2006) . Another effect of the death system Fas/Fas ligand has been described during the first steps of pregnancy. Indeed, Fas has been detected in 60% of human endometrial epithelial cells (EECs) (Galàn et al., 2000) . The authors of this article state that the apoptosis of EECs can be induced by the embryonic invasion of the luminal epithelium, the subsequent contact of the trophoectoderm with the basal membrane and, finally, the stromal invasion.
However, the experimental goal of the study was quantitative determination of the selected genes in the endometrium of the patients pregnant after ICSI cycles, with Low Density Array technology. Therefore, the presence of the endometrial genes expressed in a quantitative homogenous way in the patients who subsequently became pregnant could enable us to identify the ideal gene expression profile.
Materials and Methods

Patient selection
Women attending their first ICSI cycle at Andros Day Surgery, Reproductive Medicine Unit, Palermo, Italy, for severe male factor infertility were included in the study.
Patients that had undergone ICSI previously (both in our center or elsewhere) were not selected. Criteria for eligibility are listed in Table I . All patients enrolled in the study underwent an endometrial biopsy. It was performed under sterile conditions, from the uterine fundus, during the WOI, 7 -9 days after the midcycle urinary LH surge, using a Pipelle Catheter w (Laboratoire CCD, Paris) one or two cycles before the ICSI cycle. Furthermore, for all the women, plasma levels of progesterone (P) and prolactin (PRL) were analyzed on the same day as the endometrial biopsy. This allowed us to be certain that the biopsies were taken during the WOI.
Patients with abnormal P and PRL blood levels (P , 4 ng/ml, PRL . 25 ng/ml) were excluded. In detail, 43 women were judged eligible for the study. However, seven patients were excluded from the study: two of them achieved spontaneous pregnancy in the period between the biopsy and scheduled ICSI cycle, one refused to undergo ICSI, two showed asynchronous endometrial patterns at the histological evaluation, and two showed plasma levels of P lower than the cut-off values (4 ng/ml).
Fifteen of thirty-six patients achieved pregnancy after no more than three ICSI cycles. In all patients, ovarian stimulation was carried out using standard long protocol, as previously described (Volpes et al., 2004) .
Controlled ovarian stimulation was performed after pituitary downregulation with gonadotrophin-releasing hormone agonist (GnRHa; Leuprolide-Enantone 3.75 i.m., Takeda, Japan) administered between the 21st and the 23rd day of the previous cycle. If the biopsy was performed during the last menstrual cycle before ICSI, GnRH agonist was administered after the biopsy itself. Multifollicular development was achieved by daily injections of recombinant FSH (Gonal F, Serono, Italy) starting after at least 12 days of pituitary down-regulation. Treatment with recombinant FSH was initiated in a dose appropriate to the patient age and ultrasonic appearance of ovaries, and was adjusted to the response of the ovaries to the stimulation. Follicle growth monitoring, achieved with the use of transvaginal ultrasonography and measurement of serum estradiol, was assessed on days 6, 8 and 11 in order to evaluate possible modifications of recombinant FSH dosage. Oocyte maturation was triggered with an injection of 10 000 IU of human chorionic gonadotrophin (hCG-Gonasi HP, AMSA, Italy) after at least 10 days of FSH therapy and when at least three follicles had reached 16 mm. All oocyte pick-ups were performed trans-vaginally under ultrasound guidance and under general anesthesia, 35 -37 h after hCG administration. ICSI was carried out under an inverted microscope bearing Hoffman Modulation Contrast (Modulation Optics CO., Greenvale, NY, USA) optics. All embryo transfers were performed using a Short Frydman set (Laboratoire CCD, Paris, France) between 48 and 76 h after oocyte pick up. Pregnancy was confirmed by determining serum b-hCG concentration 14 days after oocyte retrieval in all patients. When the pregnancy test resulted positive, a second test was performed 2 days later. Ultrasound evaluations were performed 28 -32 days after oocyte pick-up, and only gestational sacs with a clear fetal heartbeat were diagnosed as clinical pregnancies. For the purpose of this study, only pregnant patients were considered for the analysis.
All patients gave written informed consent. The study was approved by the local Ethics Committee.
Tissue collection
Each endometrial biopsied tissue was divided into two portions; one portion was fixed in 10% formalin and processed for histological evaluation, while the second one was frozen in lysis buffer (Promega), at 2808C, for further RNA isolation and gene expression assay.
Histological evaluation and sample validation
Histological examination was used as further inclusion criteria. All endometrial biopsies were evaluated by the same histopathologist according to the histological criteria of Noyes et al. (1950) . Patients with any asynchronous endometrial pattern were excluded.
Criteria for gene selection
Numerous studies regarding endometrial gene expression report the involvement of more than 500 genes in the WOI (Carson et al., 2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al., 2003; Ponnampalam et al., 2004; Mirkin et al., 2005) ; in accordance with those studies, we selected 23 genes which seemed to be up-regulated, and a further 11 down-regulated genes. Moreover, 13 genes involved in the apoptosis pathway and the control gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) were included. Selected genes are listed in Table II .
RNA isolation and performance of low density array
Total RNA was isolated and purified using Maxwell TM total RNA purification standardized kit (Promega Corporation, USA), which combines the disruptive and protective properties of guanidine thiocyanate to lyse samples, denature nucleoprotein complexes and inactivate ribonucleases. The genomic DNA was selectively removed from sample lysate using the Clearing Agent. The total RNA was extracted from the cleared sample lysate using MagneSil w PMPs and was further purified from contaminant Gene expression analysis was performed using TaqMan w Low Density Array Formats 48 (Applied Biosystems, USA). In particular, in low density array experiments, it is critical to measure RNA quality and quantity accurately so as to ensure an optimal amount and purity of the cDNA; the Real-time-quantitative PCR of the GAPDH cDNA was used as control. GAPDH expression, similar in each sample, also represents a marker of RNA quality.
TaqMan w Low Density Array Formats 48 is a 48-well micro fluidic card that enabled us to run 1 -8 samples, simultaneously against 48 TaqMan Gene Expression Assays targets. The TaqMan Array functions as an array of reaction vessels for the PCR step. Typically, the wells of the TaqMan Array contain TaqMan Gene Expression Assays that detect the real-time amplification of user-specified targets.
In order to achieve a unique endometrial expression study we chose from over 47 000 inventoried TaqMan w Gene Expression Assays designed for human genes (Livak and Schmittgen, 2001 ), 48 genes (47 selected genes and 1 control gene) based on the above references.
Once the genes were selected and coded using common keywords like Entrez gene symbols, RefSeq accession numbers, or UniGene IDs and having achieved a unique TaqMan w Array panel through the Applied Biosystems Web site (www.appliedbiosystems.com), the unique gene target plate was obtained. After combining 30 -1000 ng of cDNA sample with TaqMan w Universal PCR Master Mix (for each port), the 48-well TaqMan w Array was run on the Applied Biosystem 7900HT Fast RealTime PCR System. Moreover, to obtain a homogeneous amplification curve set, a proper baseline and threshold values were optimized by Sequence Detection System (SDS) software. This software allows the storage, organization and analysis of gene expression on the 7900HT Fast Real-Time PCR System. At the end, accurate quantitative gene expression results were obtained when thermal cycling was successfully completed.
Statistical analysis
Statistical analysis was performed by using public-access software Significance Analysis of Microarrays (SAM http://www.stat.stanford.edu/ tibs/SAM) (Tusher et al., 2001) . The SAM software can perform up to 500 random permutations of group labels expressed in DCt, log10 of relative quantity of target genes, normalized in comparison to GAPDH, as control gene, to calculate the false discovery rate on the basis of t-statistics or score, assuming equal group variance. This software is used for microarray data, but it could be adopted for real-time PCR data (Bandrès et al., 2006) . The response type 'one class' was utilized, to verify which genes were homogeneously expressed with statistical significance on the basis of d-score value
Once all random permutations were performed, the SAM software reports a set of empiric d-score (Observed) (Y ) and theoretical d-score (Expected) (X ). As the empiric d i values become different from theoretical d i values, the points of the graph outdistances themselves from the straight oblique line passing through the origin (with an angle of 458). The distance between the dashed lines is the Delta threshold, which is used for detection of the homogeneous gene expression. Indeed, by using the SAM software, the points which are inside the space between the dashed lines of Delta range are not significantly different. However, the points which fall outside the space between the dashed lines of Delta range, are significantly different.
Results
Patients
A total of 43 women were eligible for the study and endometrial biopsies successfully obtained from each. However, as described in the Materials and Methods section, seven patients were excluded from the study. Fifteen out of thirty-six patients achieved pregnancy after no more than three ICSI cycles. Only the samples coming from these patients were analyzed and included in the study. The clinical characteristics of the pregnant cycles are listed in Table III .
Performance of low density array
Four out of forty-seven selected genes were excluded from the analysis, because in some patients the amplification levels of these genes did Endometrial gene expression and embryo implantation not reach the threshold value optimized by SDS software, probably due to technical problems.
Statistical analysis
The expression of 43 selected genes among 15 pregnant women was compared using the SAM software. The statistical analysis we performed highlights the fact that only 6 out of 43 selected genes showed a quantitative homogeneous expression. On the other hand, 37 out of 43 were found to be expressed in a significantly different way. Indeed, by using the SAM software, the genes inside the space between the dashed lines of the Delta range are not significantly different. Therefore, these genes are homogenously expressed and potentially correlated to the implantation process. However, the genes which fall outside the space between the dashed lines of the Delta range, are significantly different. Therefore, these genes are probably not correlated to the implantation process. Our results show that the expression values of the 6 genes, out of the 43 selected, are inside the space between the two dashed lines of the Delta threshold (width 1.15) which is used for the detection of the homogeneous gene expression. All the other 37 genes fall outside the space between the dashed lines. The False Discovery Rate is 0.1621% (Fig. 1) . Of the 43 genes analyzed, 6 genes (VEGFA, PLA2G2A, ALPL, LIF, NNMT and STC1) were shown to have homogenous expression in endometrial biopsies from all 15 patients who subsequently became pregnant.
Discussion
The data from our experimental study demonstrate that not all the genes which change their expression level during the WOI, are specifically involved in embryo implantation mechanisms. In fact, only 6 out of the 43 genes, which had been selected after a careful analysis of the publications, showed a quantitative homogeneous expression in the pregnant patients. These genes are always present and always in the same quantity; for the others, the levels of expression were extremely variable among these patients. The presence of the endometrial genes expressed in a quantitative homogenous way in the patients who subsequently became pregnant allowed us to identify the ideal gene expression profile, although our results need to be confirmed.
Among the genes we found showing a uniform expression in pregnant patients, VEGF (encoding VEGF; Vascular Endothelial Growth Factor) and LIF (encoding LIF; Leukemia Inhibitory Factor) have already been correlated to the implantation process (Smith, 2000; Yue et al., 2000) .
VEGF is a growth factor active in angiogenesis and endothelial cell growth. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Angiogenesis seems to have an important role in making the endometrium receptive to the embryo implantation. Higher serum concentration of VEGF on the day of the oocyte pick up has been correlated to the subsequent outcome of the IVF cycle (Dorn et al., 2003) . Our findings represent further evidence that angiogenesis is crucial for the implantation process.
LIF is an interleukin six class cytokine, which induces proliferation and differentiation of many types of tissues, although its action is not well understood. LIF may be involved in the differentiation of the trophoblast for the adhesion into the deciduas, as shown in in-vitro studies (Nachtigall et al., 1996) . Furthermore, LIF production in culture of endometrial tissue from women affected by idiopathic infertility is lower than that of fertile women (Delage et al., 1995) . Homogeneous LIF production in our patient group seems to confirm its role in the reproductive process. Our results and other publications indicate a trend towards a positive correlation between LIF and pregnancies, however, this is contrary to the findings of Bersinger et al. (2008) , in which LIF was down-regulated in pregnant patients. Hence, this last finding requires further elucidation.
Regarding the other four genes homogeneously expressed among pregnant women, there is no evidence for their involvement in the implantation process.
Phospholipase A2, group IIA (PLA2G2A) is a mediator of the inflammatory process and it is thought to participate in the regulation of the phospholipid metabolism in biomembranes. This gene showed an up-regulation in the ongoing pregnancies in the work of Bersinger et al. (2008) , but its role is far from being understood.
Alkaline Phosphatase (ALPL) seems to play a role in skeletal mineralization, but its exact physiological function is not known. It has been linked directly to a disorder known as hypophosphatasia, a condition characterized by hypercalcemia and it includes skeletal defects.
Nicotinamide N-methyltransferase (NNMT) catalyzes the N-methylation of nicotinamide and other pyridines to form pyridinium ions; it was identified in a genome-wide linkage search as being an important regulator of homocysteine synthesis.
Stanniocalcin 1 (STC1), homolog of a calcium regulating hormone in bony fish, is a putative regulator of mineral homeostasis, especially due to the stimulation of phosphate uptake by the renal tubule.
Further studies are required to find a link between the expression of these genes and the implantation process. Looking at the overall results, other factors, such as glycodelin-A, which is considered to be a marker of implantation (Hoozemans et al., 2004) , did not show a homogeneous expression pattern among pregnant women, so we can argue that its role needs to be more clearly elucidated.
It is widely accepted that it is very difficult to provide an experimental model for studying the endometrium during the implantation window (Maruyama and Yoshimura, 2008) . Focusing on the gene expression in a murine model, Reese et al. (2001) showed a great variability of the genes changing their expression level during implantation. Furthermore, they showed that the WOI in mice is not only a temporal period in which the blastocyst implants, but also a well-defined spatial locus that presents a different gene expression pattern, compared with inter-implantation sites. This evidence has also opened up new perspectives for the knowledge of implantation mechanisms in humans. On the basis of this, and other findings, two genes (LEPR, HOXA11) evaluated by Reese et al. (2001) were included in our gene panel; however, they did not show a homogeneous expression.
The studies that showed significant modification in the endometrial patterns of gene expression in humans, and which we used for the selection of our gene panel (Carson et al., 2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al., 2003; Mirkin et al., 2005) , used different protocols and statistical analyses. Thus it is very difficult to reach any robust conclusions and many questions arise from the analysis of these studies. Firstly, the fold change used to judge any significant modification in gene expression was arbitrarily established, in each case, possibly explaining discrepancies between studies. Secondly, we do not know the relationship between 'statistical' difference and 'biological' difference; in other words, which is the real fold change gene expression that determines a biological effect? Thirdly, it has been postulated that the genes which significantly change their expression profile during the WOI are determinant in the process of embryo implantation. Can we confirm that all genes which change their expression levels during the WOI are really involved in the embryo implantation? On the contrary, we speculate that there are some genes which are critical in the implantation process, despite having a uniform expression profile throughout the entire menstrual cycle.
Taking into account these considerations, it is possible to state that the biological bases of embryo implantation are far from being understood, and furthermore our study indicates that only a very few genes are really important for embryo attachment. A recent study (Bersinger et al., 2008) , reported changes in endometrial gene expression profiles between ongoing pregnancies and miscarriages after IVF. However, this study demonstrates particular bias: the role of the viability of the different embryos transferred. The approach of our study is totally new and differs from the aforementioned study. Instead of looking for 'differences' in gene expression profiles between pregnant and non-pregnant patients, as considered in our preliminary analysis, where we did not find any difference (Volpes et al., 2007) , we decided to analyze the endometrial gene expression levels only for patients who became pregnant after ICSI cycles, thus avoiding any bias regarding embryo viability and embryo transfer difficulties. The group of patients we selected has a proven functional endometrium as confirmed by their ongoing pregnancies.
This study is however limited, endometrial biopsies were performed one or two menstrual cycles before the ICSI cycle. Thus, it is possible that the use of both GnRH agonist and gonadotrophins could modify the endometrial gene expression, and it was beyond the scope of this investigation to compare the endometrium of a natural cycle and that of a stimulated one in the same patient. The main reason for taking the biopsy before the ICSI cycle is that we believe it is ethically questionable to perform an endometrial biopsy after the embryo transfer.
Studies comparing the endometrial gene expression between natural and stimulated cycles (Mirkin et al., 2004; Horcajadas et al., 2005; Simon et al., 2005; Martinez-Conejero et al., 2007; Liu et al., 2008) have, however, reached different conclusions. Mirkin et al. (2004) showed that although the controlled ovarian stimulation determines structural and functional changes in the endometrium compared with natural cycles, small changes were observed when gene expression profiles were compared, with no important consequence for the receptive characteristics of the stimulated endometrium. On the contrary, Horcajadas et al. (2005) reported large differences in gene expression when comparing natural and stimulated cycles (but without any progesterone supplementation). However, as the authors state, these differences could be due 'in a large part, to the lack of luteal support'. Simon et al. (2005) investigated the use of different GnRH antagonist protocols, with luteal support, and observed that the gene expression profile with a standard dose of GnRH antagonist was most similar to that of natural cycles.
Nevertheless, these observations do not have any confirmation in clinical practice: higher pregnancy and implantation rates after IVF/ ICSI cycles, in patients treated with the GnRH antagonists compared with the patients treated with GnRH agonists, have not been demonstrated (Al-Inany et al., 2006; Kolibianakis et al., 2006; Huirne et al., 2007) . This contradiction between experimental and clinical results clearly shows that we are a long way from understanding the real impact of the biomolecular studies.
Taking into account this data, it seems that controlled ovarian stimulation with luteal phase supplementation with progesterone does not induce dramatic changes in the endometrial gene expression.
Almost all published studies have stressed the differences in endometrial gene expression between the WOI and other phases of the menstrual cycle, such as the proliferative phase and early secretive phase, but there is little agreement among authors. On the other hand, certain genes uniformly expressed during the menstrual cycle might be linked to the attachment of the embryo to the uterine wall.
Considering that we are at the beginning of the application of the biomolecular approach to the physiological evaluation of the endometrium, we believe that it is better to consider similar features within a homogeneous group (e.g. women known to be able to achieve pregnancy), instead of looking for differences between groups of patients (e.g. pregnant and not pregnant) or distinct phases of the menstrual cycle. The pregnancy itself demonstrates the functionality of the endometrium, also after an ICSI cycle when gonadotrophins are used; in our opinion, to select only patients who subsequently become pregnant represents a useful experimental model.
Our study does not provide a unique model for understanding the biomolecular cascade that leads to the embryo implantation, because the genes we found homogeneously expressed do not show any functional correlation to one another. However, our results need to be confirmed by other studies. In conclusion, to the best of our knowledge, this is the first report that tries to correlate biomolecular and clinical findings.
Our future goal is to analyze other genes closely related to the six ones which showed a homogeneous expression, so that we might be able to identify the whole biomolecular cascade.
